A Phase 1 interventional study of REGN13335 and Matching Placebo in Healthy Volunteers, sponsored by Regeneron Pharmaceuticals. Completed at 1 site in New Zealand. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-19.
Sponsored by Regeneron Pharmaceuticals · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is researching an experimental drug called REGN13335. This is the first time that REGN13335 will be given to people. This study will enroll healthy adults.
The aim of the study is to see how safe and tolerable REGN13335 is in healthy volunteers.
The study is looking at several other research questions, including:
Regeneron Pharmaceuticals is the lead sponsor of 413 studies on the registry; 91 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 80 (63%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
NOTE: Other Protocol Defined Inclusion / Exclusion Criteria Apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Randomized as described in the protocol
Drug: REGN13335 · Drug: Matching Placebo
Randomized as described in the protocol
Drug: REGN13335 · Drug: Matching Placebo
Randomized as described in the protocol
Drug: REGN13335 · Drug: Matching Placebo
Randomized as described in the protocol
Drug: REGN13335 · Drug: Matching Placebo
Randomized as described in the protocol
Drug: REGN13335 · Drug: Matching Placebo
Randomized as described in the protocol
Drug: REGN13335 · Drug: Matching Placebo
Randomized as described in the protocol
Drug: REGN13335 · Drug: Matching Placebo
≤ Highest IV or SC Dose as described in the protocol Randomized as described in the protocol
Drug: REGN13335 · Drug: Matching Placebo
Administered intravenous (IV) or subcutaneous (SC), sequential ascending single dose
Administered IV or SC, sequential ascending single dose
Incidence of treatment emergent adverse events (TEAE's) through the end of the study (EOS) visit
Time frame: Baseline to day 113
Severity of TEAE's through the EOS visit
Time frame: Baseline to day 113
Concentrations of functional REGN13335 in plasma through the EOS visit
Time frame: Baseline to day 113
Incidence of anti-drug antibodies (ADA) to single doses of REGN13335 over time
Time frame: Baseline to day 113
Titer of ADA to single doses of REGN13335 over time
Time frame: Baseline to day 113
Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy.
Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Ran from Dec 2023 to primary completion in Feb 2025, 14 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.